Compare · ABT vs RNTX
ABT vs RNTX
Side-by-side comparison of Abbott Laboratories (ABT) and Rein Therapeutics Inc. (RNTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and RNTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $175.37B, about 2378.1x RNTX ($73.7M).
- Over the past year, ABT is down 18.6% and RNTX is down 39.4% - ABT leads by 20.8 points.
- ABT has hit the wire 12 times in the past 4 weeks while RNTX has been quiet.
- ABT has more recent analyst coverage (25 ratings vs 2 for RNTX).
- Company
- Abbott Laboratories
- Rein Therapeutics Inc.
- Price
- $100.68+1.91%
- $0.87-3.36%
- Market cap
- $175.37B
- $73.7M
- 1M return
- +11.09%
- -8.50%
- 1Y return
- -18.60%
- -39.38%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2017
- News (4w)
- 12
- 0
- Recent ratings
- 25
- 2
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Roman Michael F
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- EXECUTIVE VICE PRESIDENT Morrone Louis H. covered exercise/tax liability with 269 units of Common shares without par value, decreasing direct ownership by 0.35% to 76,574 units (SEC Form 4)
- Robert W. Baird initiated coverage on Abbott Labs with a new price target
- EVP, GC AND SECRETARY Cushman Elizabeth C. covered exercise/tax liability with 560 units of Common shares without par value, decreasing direct ownership by 1% to 38,013 units (SEC Form 4)
Latest RNTX
- Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom
- SEC Form DEFA14A filed by Rein Therapeutics Inc.
- SEC Form DEF 14A filed by Rein Therapeutics Inc.
- Director Von Rickenbach Josef H bought $49,561 worth of Common stock (47,060 units at $1.05), increasing direct ownership by 305% to 62,514 units (SEC Form 4)
- SEC Form PRE 14A filed by Rein Therapeutics Inc.
- Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option
- SEC Form 10-Q filed by Rein Therapeutics Inc.
- Officer Windsor James Brian bought $25,000 worth of Common stock (25,000 units at $1.00), increasing direct ownership by 1,222% to 27,046 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Rein Therapeutics Inc.
- SEC Form 8-K filed by Rein Therapeutics Inc.